The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study.
 
Yusuke Okuma
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Chugai Pharma (Inst); Ono Pharmaceutical
 
Kaoru Kubota
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Kirin; Lilly Japan; MSD Oncology; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Mototsugu Shimokawa
No Relationships to Disclose
 
Kana Hashimoto
No Relationships to Disclose
 
Yosuke Kawashima
Honoraria - AstraZeneca/Hong Kong; Chugai Pharma; Kyowa Kirin; Life Technologies; Lilly O.; Taiho Pharmaceutical
 
Tomohiro Sakamoto
Speakers' Bureau - Amgen; AstraZeneca; Chugai Pharma; Hisamitsu Pharmaceutical; Illumina; Janssen; Kyowa Kirin; Lilly; Lilly; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Hiroshi Wakui
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyouwa Kirin; Lilly; MSD; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; UCB
 
Shuji Murakami
Honoraria - AstraZeneca; Chugai Pharma; Lilly O.; MSD K.K; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca; Chugai Pharma; Ono Pharmaceutical
 
Kyoichi Okishio
Speakers' Bureau - AstraZeneca/Hong Kong; Bristol-Myers Squibb; Chugai Pharma; Nippon Kayaku; Takeda
 
Kenji Hayashihara
No Relationships to Disclose
 
Yuichiro Ohe
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Anheart Therapeutics; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Janssen (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)